DMTK DermTech, Inc.

DermTech is the global leader in molecular dermatology. Our patented technology allows the analysis of skin biopsy samples collected non-invasively using an adhesive patch. Using this technology, we market and develop non-invasive gene expression tests to aid the clinical diagnosis of skin cancer, to assess inflammatory diseases, and to personalize drug treatment. Our mission is to transform dermatology by delivering highly accurate, objective information to physicians that improves care, reduces costs, and improves patient satisfaction.

$19.70  -0.73 (-3.57%)
As of 11/26/2021 13:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Diagnostics & Research
Index country:  USA
Country of incorporation:  USA
IPO date:  08/10/2017
Outstanding shares:  29,717,198
Average volume:  653,770
Market cap:   $607,122,355
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    24984K105
ISIN:        US24984K1051
Sedol:      BKS3LH4
Valuation   (See tab for details)
PE ratio:   -9.48
PB ratio:   2.32
PS ratio:   56.25
Return on equity:   -24.50%
Net income %:   -571.85%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy